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UDP-Glucose Dehydrogenase Inhibition Assay
Standard preparation: A 0.50 M Gly-Gly buffer (pH 8.7 at 25 °C) was prepared by dissolving 1.62 g of Gly-Gly in 22 mL nanopure water, pH adjusted to 8.7 with 9 M potassium hydroxide and then diluted to 25 mL with nanopure water all while being shaken at 25 °C. Solutions of UDPG and NAD + were prepared by dissolving 1.7 mg and 4.5 mg, respectively, into nanopure water resulting in 2 mM and 10 mM solutions, respectively. Preparation of the 0.1 mM 6TU solution was done by dissolving 1.8 mg into 95.5 mL of nanopure water, pH was adjusted to 9.5 with a 2 M sodium hydroxide solution (for solubility), pH adjusted to 7.5 with a 0.5 M hydrochloric acid solution (a dilute solution of HCl is required to prevent thiol oxidation), and then diluted to 100 mL. All other purine samples were prepared in an analogous fashion to desired concentrations. A 5 unit/mL UDPGDH solution was prepared by dissolving 0.11 mg of UDPGDH in 0.8 mL of 0.5 M Gly-Gly while stirring; once dissolved, the solution was diluted to volume with gly-gly in a 1 mL volumetric flask. All solutions were kept at 4 °C when not in use.
UDP-glucuronosyltransferase activity assay
Standard preparation: A bilirubin stock solution was prepared by dissolving bilirubin in 100% dimethyl sulfoxide to yield a concentration of 2 mM, the stock solution was aliquoted, and stored at -70 °C until use. A 25 mM UDPGA stock solution was prepared by diluting 8 mg to 0.5 mL with nanopure water, and a 10 mg/mL alamethicin solution was prepared by taking 5 mg and diluting to 500 µL with methanol. Preparation of the 100 mM potassium dihydrogen phosphate buffer was done by dissolving 2.3 g of KH2PO4 into 80 mL of nanopure water, pH adjusted to 7.4 with 1 M HCl and diluted to volume in a 100-mL volumetric flask.
Chromatographic Conditions -Bilirubin and Bilirubin Glucuronide: Bilirubin and its
glucuronide were separated on a Discovery C18 analytical column, 4.5 mm x 100 mm, 5 µM S 20 particle size with guard column. A dual mobile phase was employed; the aqueous phase consisted of an 8 mM imidazole & 2.5 mM tetrabutylammonium hydrogen sulfate (TBAHS) buffer at a pH of 6.5 in nanopure water and acetonitrile as the organic phase. A gradient elution profile was employed for full separation at a flow rate of 0.5 mL/min, the method begins at 10% acetonitrile and increases to 50% over 8 minutes, held for 5.5 minutes, increased to 95% over 4.5 minutes, held for 10 minutes, returned to 10% over 4 minutes and held at 10% for 2 minutes to allow for column regeneration. The detection wavelength was 450 nm with a sample injection volume of 5
µL. The combined peak area for bilirubin (sum of the three isomers) was plotted relative to the concentration prepared for the generation of a working standard curve. 
Quantification of Bilirubin, and Mono/Di-glucuronide Levels:
A total of ten peaks for the glucuronide species, including their isomers were detected in the incubation samples. Peak assignment and identification of UCB, BMG1, BMG2, BDG and their isomers were based on their lipophilicity and polarity, as well as the elution pattern, chromatographic peak position and relative S 21 retention time from previous reports. [1] [2] [3] [4] The calibration curves for bilirubin were used to determine the concentration of the mono-and di-glucuronide species employing the gradient HPLC bilirubin method described above. Figure S2 : Reaction progressive curve for bilirubin: Bilirubin consumption was measured in a UGT1A1 catalyzed reaction every 15 minutes for two-hour period and bilirubin level went down linearly for 1 hour. Therefore, glucuronidation reaction was carried out for 45 minutes for inhibition assay. The mixture was allowed to shake at 37 °C for each of the time course experiments. To each reaction 600 µL of ice-cold methanol containing 200 mM ascorbic acid was added to terminate the enzymatic reaction, vortexed for 2 min, and then centrifuged at 12,000 rpm for 10 min. The supernatant was then analyzed by the developed gradient HPLC protocol for separation and quantification of UCB, BMG1, BMG2, and BDGs.
Regorafenib and Sorafenib Inhibition Assessment Towards UGT-1A and UDPGDH
Supplemental Table S1 . Inhibitor assessment of known UGT inhibitors sorafenib and regorafenib towards UGT (left) and UDPGDH (right). Inhibitors were dissolved in DMSO, as such controls with no inhibitors used had the same volume of DMSO added for direct comparison of the inhibition assessments. Each analyte is an average of three independent runs with standard error bars (SEBs). Many SEBs are not visible due to small value of the error. (n=3)
